Market access from Day One: Navigating the new era of global pricing interdependence

The pharmaceutical industry is entering a period of unprecedented disruption.

For decades, global pricing and market access evolved through slow, incremental regulatory shifts. Today, however, the rules are changing faster than manufacturers can comfortably react. This is driven largely by the US, but reinforced by parallel policy reforms across Europe, Canada, China and other major markets. These forces are not operating in isolation; they are unleashing knock-on effects, creating a level of interconnectedness the industry has never had to manage at this scale.

Against this backdrop, colleagues from LCP Health Analytics – Dr Jasim Uddin, Kevin Patterson, and Tim Moore joined Jeff Henderson, former Head of Market Access at Ironwood Pharma and Vectiv Bio, for a webinar exploring how these global dynamics are transforming pricing strategy and evidence generation.

Their combined backgrounds brought a unique 360‑degree perspective: Jasim’s expertise in global policy and value frameworks, Kevin’s insight into the structural logic behind pricing systems, Tim’s strategic and commercial focus, and Jeff’s deep experience navigating US and global access, contracting and the evolving supply chain.

Their discussions delivered a key message: the period ahead requires profoundly different thinking, where earlier planning involving all relevant stakeholders is key to ensuring optimal patient access to innovative new therapies.

Why this conversation matters now

The shift began with what many once viewed as theoretical: US alignment to international drug pricing. The theory has now shifted to practical reality with the recent emergence of most-favoured-nation (MFN) style approaches, which tie US payment benchmarks to Organisation for Economic Co-operation and Development (OECD) markets, pulling the US into the global pricing ecosystem in ways that will fundamentally influence launch sequencing, price corridor design and cross‑market spillover effects. The panellists highlighted a key strategic consideration:

“US pricing can no longer be insulated by commercial dynamics alone and every decision in Europe, Canada and even smaller reference markets carries potential downstream impact.”

At the same time, transparency pressures are intensifying. Net price disclosures, pharmaceutical benefit manager (PBM) transparency provisions, and stricter reporting requirements across value transfers are exposing previously opaque channels, from discounts and rebates to patient support structures. Jeff emphasised how the implications extend beyond payer negotiations to channel strategy, 340B mitigation, and even tariff‑related supply chain planning.

Globally, markets are responding in their own ways. The EU is progressing through Joint Clinical Assessment (JCA) implementation and pharma package reforms, reshaping evidence expectations, assessment timelines, exclusivity structures, and launch considerations, particularly for smaller biotechnology companies navigating resource‑intensive processes with overlapping regulatory and health technology assessment (HTA) demands.

Meanwhile, countries like France and Germany are recalibrating pricing strategies in response to MFN effects, and Canada’s Patented Medicine Prices Review Board (PMPRB) is tightening list‑price discipline through more defined international reference thresholds.

The result is a global landscape where policy changes echo across borders, magnifying the consequences of every local decision.

What is driving the change?

Three themes dominated the panel’s reflections:

The US is becoming a global price‑taker

MFN mechanisms, inflation reduction act (IRA) negotiation timelines and expanding inflation rebates mean the US is increasingly basing its decisions on the actions of other developed countries rather than operating independently. This introduces entirely new constraints on global pricing freedom and incentivises manufacturers to withdraw, delay or reprioritise launches in certain European markets to protect US price positions.

Evidence expectations are converging

If MFN and JCA push the US closer to HTA‑style value assessment, manufacturers must rethink evidence generation. The panel underscored how patient-reported outcomes (PROs), quality of life (QoL) measures, healthcare resource utilisation (HCRU) and long‑term outcomes must be built into pivotal programs far earlier, often beginning in Phase 2, with market access playing a central role in study design. Many organisations still struggle to invest early, creating costly downstream gaps when payers later request evidence the clinical program was not built to generate.

Global pricing interdependence is now unavoidable

External reference pricing, parallel trade, transparency registries and updated price baskets mean visible list prices matter more than ever. Markets once treated as “lower priority” could now carry meaningful international reference pricing (IRP) risk, forcing companies to take a more deliberate, globally coordinated approach to price corridor planning and launch sequencing.

A more strategic future

Throughout the conversation, a common theme emerged: proactive strategies should take precedence over reactive ones.

Our colleagues observed that numerous top companies now form global value committees early in the development process, design comprehensive risk matrices to connect list and net price risks, conduct launch simulations across various policy settings, and develop global value stories long before submitting to regulatory authorities. These organisations increasingly confront complex decisions regarding indication and launch order because clinical and reimbursement factors vary both within and across countries worldwide. The volume and sophistication of information needed for thorough early discussions is expanding rapidly.

Early value discussions are especially critical for biotechnology companies. With increasing evidence requirements, earlier involvement in market access considerations, complex global pricing constraints, and the necessity to demonstrate value across multiple HTA systems, early-stage organisations must not postpone access planning until Phase 3. This is particularly relevant as private equity and major pharmaceutical companies have begun to re-engage with biotechnology firms earlier in the clinical development process.

A new model for global market access

The market is undeniably moving toward more interconnected, more transparent and more rigorously assessed pricing. As US, EU and global policy reforms continue to collide and reinforce each other, the companies that will succeed are those that treat pricing and market access not as downstream operations, but as an early strategic discipline that shapes clinical development, investment decisions and long‑term portfolio viability.

For LCP Health Analytics and its experts, one thing stands out above all:

“In a world where borders matter less and global policy forces matter more, market access must begin on day one – with foresight, rigour and coordination guiding every step.”

This article was originally published in the The Evidence Base, 9 March 2026.